A
`TRENDING
`
`
`# FIERCE SPECIALREPORTS©PHARMAMANUFACTURING MARKETING VACCINES TOPICS
`
`
`
`
`
`
`
`Pharma
`
`Novartishot new eye drug Beovu tied to
`potential vision loss: experts
`
`by Eric Sagonowsky | Feb 24, 2020 3:22pm
`
`720
`if »
`NOC 007B0827-61
`5
`Beovu"™
`gE
`|
`;
`(brolucizumad-dbll)
`Injection
`. =_ne
`
`f
`
`th NOVARTIS
`
`Ee
`es ‘
`
`mow
`
`6 mg/0.05mL.
`sreeYat Deed oe
`
`Sunday, the American Society of Retina Specialists sent out a communication over serious side effects for
`Novartis’ Beovu. (Novartis)
`
`Novartis has touted early successfor its new eye drug Beovu, but an alert
`tying the drug to potential vision loss might cause docs to balk when it comes
`to prescribing the medicine.
`
`RESOURCE CENTER
`
`SIE
`
`Expand drug market
`
`accessin 3 key steps
`
`Webinar
`Expand Drug Market Accessin
`3 Key Steps
`
`
`
`Commercializing Diagnostic
`Tests: Achieving Commercial
`Success with a Complete
`Market View
`
`Sa
`
`a
`panies
`
`Webinar
`Exploring Rare Disease
`through a Data-Driven Lens
`
`The American Society of Retina Specialists (ASRS) issued a note Sunday
`night to members about14 casesofretinal vasculitis for Beovu patients,11 of
`which were occlusive retinal vasculitis that can lead to vision loss, Piper
`Sandler analyst Christopher Raymondwrote in a Monday noteto clients.
`That's a side effect that so farhasn't plagued other drugs in the anti-VEGF a a
`class, which includes Regeneron's Eylea. One doctor told Raymond “his entire
`practice would not be ordering Beovu, but anyone who has, should likely
`ibscribe to
`F
`‘freak out' upon reading" the ASRS communication, the analyst wrote.
`Pharma t
`and
`justry news
`ipdates
`delivered
`ur
`inbo:
`
`UPCOMING WEBINAR
`
`How to choose the appropriate pre-filled
`syringe and enhanceddelivery system for
`your product
`Whatdo! need to consider when deciding on a delivery system? How can! prove
`thatit will be safe and effective and comply with regulatory authority
`requirements? In an environmentthat calls for more convenientdelivery systems,
`we will guide you on how to make the right choice for your product. This webinar
`will cover selection criteria for pre-filled syringes and enhanced delivery systems.
`
`Register Today
`
`Ofcourse,thealert is “fresh” and that’s only one doctor's opinion, Raymond
`stressed. But shareholders didn't take kindly to the news, sending shares
`downabout 5.5% Monday afternoon.Alternatively, Regeneron's shares have
`jumped more than 15% on the news.
`
`Novartis has “engaged an external safety review committee to further
`evaluate these post-marketing cases," a spokesman said, adding that the
`drugmaker would also do its own internal assessment. "Patient safety is of
`paramountimportance," he said, adding that “wewill continue to share
`details as they becomeavailable."
`
`RELATED: Novartis has its blockbuster Beovu OK, but its ‘hot mess' label
`leaves something to be desired: analysts
`
`emt
`
`Subscribe
`
`acknowledge that
`eceive
`emails
`fr
`FiercePt
`a and
`f their
`
`on
`
`behalf
`
`Aboutthe Author
`Eric Sagonowsky
`Senior Editor
`
`In the short term, the side effects will likely “dampen retina physicians’initial
`uptake of Beovu,” Jefferies analyst Peter Welford wrote in a note
`Tuesday. The long-term impact will dependonthe safety review. Fornow,
`Welford expects that some doctors will wait for their first Beovu patients to
`get more injections before adopting the drug on a widerscale.
`
`Exhibit 2193
`
`Page 01 of 02
`
`M yla nV. Reg eneron
`| P R2 02 1 -0 088 1
`U.S. Pat. 9,254,338
`Exhibit 2193
`
`Exhibit 2193
`Page 01 of 02
`
`

`

`Z
`
`Pharma
`VACCINES
`MARKETING
`MANUFACTURING
`FIERCE
`“| was an early adopter and quit as of yesterday,” he wrote.
`
`TRENDING
`TOPICS
`
`SPECIAL REPORTS
`
`PHARMA
`
`Beovu, which won approvalin Octoberto treat wet age-related macular
`degeneration, representsa critical new launch for Novartis in a competitive
`field. After Beovu's FDA greenlight,it pulled in $35 million during
`the fourth quarter.
`
`RELATED: Novartis‘ new Eylea challenger Beovu has docs excited: exec
`
`As of Novartis’ earnings call in late January, the company was off to a “great
`start”with the rollout, pharma chief Marie-France Tschudin said. The
`company has heard positive customer feedback and seen “very strong
`uptake”from retina specialists, she added.
`
`Read More On
`
`drug safety
`
`analysts Novartis Beovu
`
`CONTACT
`Advertise
`About Us
`
`GENERAL
`Home
`Privacy
`Terms Of Use
`RSS
`
`NEWSLETTERS
`Subscribe
`
`CONNECT
`
`Exhibit 2193
`
`Page 02 of 02
`
`Exhibit 2193
`Page 02 of 02
`
`